Articles & Video
Clinical Trials Content Library: Whitepapers and Reports Collection
Explore our collection of exclusive whitepapers and reports covering the hottest topics in clinical trials with one simple registration.
Four things biotech and small pharma should know before selecting a CRO
This whitepaper offers a guide to biotechs and smaller pharma companies when looking to successfully partner with a CRO to outsource clinical trials.
The Top 10 Posts of 2019: Clinical Trials Innovation
We look back at 2019's most popular articles on innovating clinical trials in an interactive flip-book.
Virtual trials and Real World Evidence: The global shift in clinical operations
We deep-dive into our State of the Industry Report 2019 to understand how companies are utilizing virtual trials and Real World Evidence in their clinical trial operations.
Using adaptive design and biomarkers in early phase clinical trials - INDUSTRY VOICES
Clinical trial experts gave us their view on the current potential for using adaptive design and biomarkers in early phase clinical trials.
Leveraging Real World Evidence for drug approval
Since the introduction of the 21st Century Cures Act real world evidence has been gaining in popularity. We look at the opportunities and challenges it presents.
Real World Evidence: Revolutionizing the Clinical Trials Environment - WHITEPAPER
Download this exclusive whitepaper exploring how Real World Evidence is revolutionizing the clinical trials environment.
How Virtual Trials and Real World Evidence are changing the CRO landscape
Dr. Raphaela Schnurbus, Clinical Solutions & Business Development Director at CRO OPIS, explores how Virtual Trials and Real World Evidence could change the clinical trials of the future.
Real-World-Evidence Mythbusting: 5 myths holding back patient-reported RWE adoption
What is holding back patient-reported Real-World-Evidence adoption in clinical trials? Bruce Hellman, CEO and Co-founder at uMotif, busts 5 myths.
The potential of smart adherence tools in clinical trials
Dr Hilde Vanaken, Clinical Innovation Director at Janssen, explores the opportunities around smart adherence tools as well as the implementation barriers.